US 20250122198A1
· Lindsley
· 2025
[cited by examiner]
US 20250122200A1
· Lindsley
· 2025
[cited by examiner]
US 20250122201A1
· Lindsley
· 2025
[cited by examiner]
WO WO2017107087A1
· 2017
[cited by applicant]
WO WO2017112719A1
· 2017
[cited by applicant]
WO WO2018112840A1
· 2018
[cited by applicant]
WO WO2018118736A1
· 2018
[cited by applicant]
WO WO2022015988A1
· 2022
[cited by applicant]
U.S. Appl. No. 19/002,083, Lindsley et al., filed Dec. 26, 2024.
[cited by applicant]
U.S. Appl. No. 19/002,103, Lindsley et al., filed Dec. 26, 2024.
[cited by applicant]
U.S. Appl. No. 19/002,334, Lindsley et al., filed Dec. 26, 2024.
[cited by applicant]
U.S. Appl. No. 19/002,355, Lindsley et al., filed Dec. 26, 2024.
[cited by applicant]
“1,2-DIBROMOETHANE-D4 (D, 99%), Safety Data Sheet,” Cambridge Isotope Laboratories, Inc., 2017, Version 3.0, 10 pages.
[cited by applicant]
Ao et al., “Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK),” Journal of Labelled Compound…
[cited by applicant]
Bodick et al., “Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease,” Archives of Neurology, 1997, 54(4):465-473.
[cited by applicant]
Bubser et al., “Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents,” ACS Chemical Neuroscience, 2014, 5(10):920-942.
[cited by applicant]
Bymaster et al., “Potential role of muscarinic receptors in schizophrenia,” Life sciences, 1999, 64(6-7):527-534.
[cited by applicant]
Bymaster et al., “Unexpected anti psychotic-like activity with the muscarinic receptor ligand (5R, 6R) 6-(3-3 propylthio-1, 2, 5-thiadiazol-4-yl)-1-azabicyclo [3.2.1] octane,” European Journal of Pharmacology, 1998, 356…
[cited by applicant]
CAS No. 22581-63-1, “1,2-Dibromoethane-d4,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/aldrich/425362>, 9 pages.
[cited by applicant]
CAS No. 530-62-1, “1,1′-Carbonyldiimidazole,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/mm/802301>, 9 pages.
[cited by applicant]
CAS No. 937-14-4, “3-Chloroperbenzoic acid,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/aldrich/273031>, 12 pages.
[cited by applicant]
Conde-Ceide et al., “Discovery of VU0409551/JNJ-46778212: An mGlu5 positive allosteric modulator clinical candidate targeting schizophrenia,” ACS Medicinal Chemistry Letters, 2015, 6(6):716-720.
[cited by applicant]
Felts et al., “Discovery of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy) picolinamide (VU0424238): a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinical eval…
[cited by applicant]
Garrison et al., “Development of VU6019650: a potent, highly selective, and systemically active orthosteric antagonist of the M5 muscarinic acetylcholine receptor for the treatment of opioid use disorder,” Journal of Me…
[cited by applicant]
Gleason et al., “Deuterium: Natural Variations Used as a Biological Tracer,” Science, 1970, 169:1085-1086.
[cited by applicant]
Harbeson et al., “Chapter 24: Deuterium in Drug Discovery and Development,” Annual Reports in Medicinal Chemistry, 2011, 46:404-417.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2024/035078, mailed on Oct. 8, 2024, 12 pages.
[cited by applicant]
Johnson et al., “Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders,” BioMedicines, 2022, 10(398):1-36.
[cited by applicant]
Morris et al., “Discovery of (S)-2-Cyclopentyl-N-((1-Isopropylpyrrolidin2-Y1)-9-Methyl-1-Oxo-2, 9-Dihydro-1 H-Pyrrido [3, 4-b] Indole-4-Carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (G…
[cited by applicant]
Shannon et al., “Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats,” Journal of Pharmacology and Experimental Therapeutics, 1999, 290(2):901-9…
[cited by applicant]
Shannon et al., “Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice,” Schizophrenia Research, 2000, 42(3):249-259.
[cited by applicant]
Spock et al., “Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist,” ACS Medicinal Chemistry Letters, 2021, 12:1342-1349.
[cited by applicant]
Stanhope et al., “The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat,” The Journal of Pharmacology and Experimental Therapeutics, 2001, 299(2):782-792.
[cited by applicant]
Yu et al., “Discovery of ethyl ketone-based highly selective HDACs 1, 2, 3 inhibitors for HIV latency reactivation with minimum cellular potency serum shift and reduced hERG activity,” Journal of Medicinal Chemistry, 20…
[cited by applicant]